YMR187C Antibody

What is YMR187C and why is it relevant for research?

YMR187C is a non-essential yeast gene encoding a putative protein of unknown function in Saccharomyces cerevisiae . Despite its unknown function, this protein has garnered research interest, particularly in the context of neurodegenerative disease models.

Methodological Answer: When investigating proteins of unknown function like YMR187C, researchers should employ multiple approaches:

• Bioinformatic analysis for structural predictions and homology identification

• Phenotypic characterization of deletion mutants (ymr187cΔ)

• Protein localization studies using fluorescent tags

• Interaction mapping via techniques such as yeast two-hybrid or affinity purification

• Transcriptional regulation analysis under various stress conditions

YMR187C's relevance stems from its potential role in fundamental cellular processes and its utility in yeast-based model systems for human diseases, particularly tauopathies like Alzheimer's disease .

What are the key specifications of commercially available YMR187C antibodies?

Commercial YMR187C antibodies are primarily research tools designed for specific laboratory applications. Understanding their specifications is crucial for experimental design.

Methodological Answer: When selecting a YMR187C antibody, researchers should consider the following specifications:

These specifications directly impact experimental outcomes and should be carefully evaluated based on the research objectives .

How should researchers validate YMR187C antibody specificity before use?

Methodological Answer: Antibody validation is a critical step to ensure experimental reliability. For YMR187C antibody, implement the following validation protocol:

• Primary validation:

  • Western blot analysis comparing wild-type vs. ymr187cΔ strains

  • Peptide competition assay to confirm epitope specificity

  • Testing antibody on recombinant YMR187C protein of known concentration

• Secondary validation:

  • Cross-checking results with alternative detection methods (e.g., mass spectrometry)

  • Immunoprecipitation followed by mass spectrometry to confirm target binding

  • Testing on multiple yeast strains to ensure consistent recognition

• Controls to include:

  • Positive control: Overexpressed YMR187C

  • Negative control: ymr187cΔ strain

  • Technical control: Secondary antibody only

Remember that antibody specificity is application-dependent, so validation should be performed for each specific application (WB, ELISA, etc.) .

What are the optimal conditions for using YMR187C antibody in Western blotting?

Methodological Answer: Optimizing Western blot protocols for YMR187C detection requires careful consideration of multiple factors:

• Sample preparation:

  • Lysis buffer recommendation: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, protease inhibitor cocktail

  • Include phosphatase inhibitors if studying post-translational modifications

  • Optimal protein load: 20-40 μg of total protein per lane

• Gel selection and transfer:

  • 10-12% polyacrylamide gel recommended based on YMR187C's molecular weight

  • PVDF membrane preferred over nitrocellulose for stronger protein binding

  • Transfer conditions: 100V for 1 hour or 30V overnight at 4°C

• Antibody conditions:

  • Blocking: 5% non-fat dry milk in TBST (1 hour at room temperature)

  • Primary antibody dilution: 1:500 to 1:1000 in 5% BSA/TBST

  • Incubation: Overnight at 4°C with gentle agitation

  • Secondary antibody dilution: 1:5000 anti-rabbit HRP conjugate

  • Washing: 3 × 10 minutes with TBST after each antibody incubation

• Detection:

  • Enhanced chemiluminescence (ECL) recommended

  • Exposure time: Start with 30 seconds and adjust as needed

• Troubleshooting common issues:

  • High background: Increase blocking time, decrease antibody concentration

  • No signal: Check protein transfer, increase antibody concentration or incubation time

  • Multiple bands: May indicate degradation, post-translational modifications, or cross-reactivity

Always include appropriate positive and negative controls, particularly ymr187cΔ strain lysate as a specificity control .

How can YMR187C antibody be used to study protein-protein interactions?

Methodological Answer: YMR187C has been reported to have 39 interactors with 46 documented interactions . To study these interactions:

• Co-immunoprecipitation (Co-IP):

  • Prepare cell lysate under non-denaturing conditions

  • Incubate lysate with YMR187C antibody (5 μg antibody per 1 mg protein)

  • Capture antibody-protein complexes with Protein A/G beads

  • Analyze precipitated proteins by mass spectrometry or Western blot

• Proximity-based labeling:

  • Generate YMR187C fusion with BioID or APEX2

  • Express in yeast cells and activate the labeling enzyme

  • Purify biotinylated proteins using streptavidin beads

  • Identify interacting proteins by mass spectrometry

• Validation approaches:

  • Reciprocal Co-IP with antibodies against suspected interactors

  • Yeast two-hybrid or split-protein complementation assays

  • Fluorescence co-localization studies

  • FRET/BRET assays for direct interaction detection

• Data analysis considerations:

  • Compare with known interactors from BioGRID database

  • Use appropriate statistical methods to filter out non-specific binders

  • Consider the biological context of each interaction

When interpreting results, remember that protein-protein interactions may be condition-dependent and transient, so negative results do not necessarily rule out interactions under different physiological conditions or time points .

What controls are essential when using YMR187C antibody in immunofluorescence studies?

Methodological Answer: Immunofluorescence studies with YMR187C antibody require rigorous controls to ensure reliable data interpretation:

• Primary controls:

  • Negative genetic control: ymr187cΔ strain

  • Secondary antibody only control: To assess non-specific binding

  • Peptide competition control: Pre-incubate antibody with immunizing peptide

• Procedural controls:

  • Fixation control: Compare different fixation methods (paraformaldehyde vs. methanol)

  • Permeabilization control: Optimize detergent concentration

  • Blocking control: Test different blocking agents (BSA vs. normal serum)

• Validation controls:

  • Orthogonal method: Compare with GFP-tagged YMR187C localization

  • Co-localization markers: Include known compartment markers

  • Signal specificity: Test antibody on cell types with variable expression levels

• Advanced controls:

  • Super-resolution microscopy to confirm subcellular localization

  • Live-cell imaging with complementary techniques

  • FRAP (Fluorescence Recovery After Photobleaching) to assess dynamics

• Quantification recommendations:

  • Measure signal-to-noise ratio across multiple fields

  • Perform colocalization analysis using appropriate coefficients (Pearson's, Manders')

  • Use automated, unbiased quantification methods

Implementation of these controls will help distinguish genuine YMR187C localization from artifacts or non-specific signals, critical for accurate interpretation of subcellular distribution patterns.

How can YMR187C antibody be utilized in yeast models of neurodegenerative diseases?

Yeast models have emerged as valuable tools for studying neurodegenerative diseases, including tauopathies like Alzheimer's disease.

Methodological Answer: To leverage YMR187C antibody in neurodegenerative disease models:

• Expression analysis during proteotoxic stress:

  • Monitor YMR187C expression levels in yeast models expressing human tau or beta-amyloid proteins

  • Compare expression in wild-type vs. tau-expressing yeast using Western blot quantification

  • Assess correlation between YMR187C levels and tau toxicity phenotypes

• Co-localization studies:

  • Perform double immunofluorescence with YMR187C antibody and anti-tau antibodies

  • Analyze whether YMR187C colocalizes with tau aggregates or other pathological structures

  • Quantify co-localization coefficients under different conditions or disease stages

• Genetic interaction analysis:

  • Use YMR187C antibody to assess protein levels in tau-expressing yeast with various genetic backgrounds

  • Compare YMR187C expression and modification in tau toxicity enhancer/suppressor strains

  • Particularly valuable in mir1Δ-tau40 strains, which show enhanced tau toxicity

• Compound screening applications:

  • Use YMR187C antibody to monitor protein changes in drug screening platforms

  • Assess whether compounds that suppress tau toxicity affect YMR187C levels or modifications

  • Incorporate into Global Platform Screening for Drug Discovery (GPSD2™) methodology

Research indicates that YMR187C might be involved in pathways relevant to tau-mediated toxicity, potentially through mitochondrial function, as suggested by studies with the mir1Δ strain (which lacks the mitochondrial phosphate carrier) .

What are the considerations for analyzing post-translational modifications of YMR187C?

Methodological Answer: Analyzing post-translational modifications (PTMs) of YMR187C requires specialized approaches:

• Detection methods:

  • Phosphorylation: Use phospho-specific antibodies or Phos-tag gels

  • Ubiquitination: Immunoprecipitate YMR187C and probe with anti-ubiquitin antibody

  • Acetylation/Methylation: Immunoprecipitate and analyze by mass spectrometry

  • SUMOylation: Use SUMO-trap pulldowns followed by YMR187C antibody detection

• Experimental design:

  • Temporal analysis: Monitor PTMs across cell cycle or stress response time courses

  • Stimulus-dependent changes: Compare PTM profiles under different growth conditions

  • Enzyme inhibitor studies: Use specific inhibitors to identify responsible enzymes

• Data from existing resources:

  • BioGRID indicates YMR187C has at least one PTM site

  • Compare with phospho-proteomics datasets from yeast

  • Analyze conservation of modification sites across species

• Functional significance assessment:

  • Generate point mutations at modification sites

  • Perform phenotypic analysis of mutants

  • Compare cellular localization of wild-type vs. PTM-site mutants

• Technical considerations:

  • Sample preparation should preserve PTMs (use phosphatase/deubiquitinase inhibitors)

  • Consider enrichment steps for low-abundance modifications

  • Use appropriate controls (phosphatase-treated samples for phosphorylation studies)

Understanding YMR187C PTMs may provide insights into its regulation and function, particularly in response to cellular stresses associated with neurodegenerative disease models .

How does the specificity profile of YMR187C antibody impact experimental outcomes?

Methodological Answer: Antibody specificity directly impacts experimental reliability and interpretation:

• Cross-reactivity considerations:

  • YMR187C belongs to a family of proteins; antibodies may recognize related proteins

  • Cross-species reactivity: Consider homology with proteins in other yeast species

  • Epitope-specific binding: Different antibody clones may recognize distinct protein regions

• Specificity profile analysis:

  • Perform epitope mapping to identify the exact binding region

  • Use bioinformatics to identify proteins with similar epitopes

  • Test antibody on arrays containing related and unrelated proteins

• Impact on experimental outcomes:

  • False positives: Cross-reactivity may lead to misidentification of interactors

  • False negatives: Epitope masking (by PTMs or protein interactions) may prevent detection

  • Quantification errors: Non-specific binding may skew quantitative analyses

• Advanced specificity engineering:

  • Consider custom antibody development using unique peptide regions

  • Apply computational approaches to predict and design for improved specificity

  • Employ machine learning models to optimize antibody-epitope interactions

• Documentation and reporting:

  • Maintain detailed records of all validation experiments

  • Report specificity profiles in publications

  • Consider multiple antibodies targeting different epitopes for critical experiments

Recent advances in antibody design utilize biophysics-informed modeling combined with selection experiments to create antibodies with customized specificity profiles, offering promising approaches for generating highly specific antibodies against challenging targets like YMR187C .

How should researchers troubleshoot non-specific binding issues with YMR187C antibody?

Methodological Answer: Non-specific binding is a common challenge that requires systematic troubleshooting:

• Diagnostic approaches:

  • Perform side-by-side comparison with ymr187cΔ strain

  • Analyze molecular weight patterns of non-specific bands

  • Test multiple blocking agents (BSA, milk, casein, commercial blockers)

  • Perform peptide competition assay to identify genuine signals

• Optimization strategies for Western blotting:

  • Increase blocking time and concentration

  • Reduce primary antibody concentration (try serial dilutions)

  • Add 0.1% Tween-20 to antibody dilution buffer

  • Increase washing steps (number and duration)

  • Use high-salt washing buffer (up to 500 mM NaCl) for stringent washing

  • Consider overnight washing at 4°C for problematic cases

• Immunoprecipitation optimization:

  • Pre-clear lysates with Protein A/G beads

  • Use cross-linked antibodies to prevent heavy/light chain detection

  • Employ denaturing conditions to reduce co-immunoprecipitation

  • Consider tandem purification approaches

• Decision tree for persistent issues:

  • If background occurs in negative controls: Focus on blocking and washing

  • If specific problematic bands appear: Consider additional purification steps

  • If general high background: Review storage conditions and antibody quality

• Alternative approaches:

  • Consider epitope tagging of YMR187C and use commercial tag antibodies

  • Use orthogonal detection methods (mass spectrometry)

  • Try alternative antibody clones if available

Implementing these strategies systematically while changing one variable at a time will help identify the optimal conditions for specific YMR187C detection .

What bioinformatic resources can complement YMR187C antibody-based research?

Methodological Answer: Bioinformatic resources can significantly enhance antibody-based research on YMR187C:

• Sequence and structure analysis:

  • UniProt (Q03236): For sequence information and annotated features

  • Pfam/InterPro: To identify functional domains

  • AlphaFold/RoseTTAFold: For predicted 3D structure

  • ConSurf: For evolutionary conservation analysis

• Interaction networks:

  • BioGRID: Contains 39 interactors and 46 interactions for YMR187C

  • STRING: For functional protein association networks

  • GeneMANIA: For gene function predictions

  • Cytoscape: For network visualization and analysis

• Expression and regulation:

  • Saccharomyces Genome Database (SGD): For comprehensive yeast data

  • SPELL: For co-expression analysis

  • YeastMine: For integrated data mining

  • YEASTRACT: For transcriptional regulation

• Comparative genomics:

  • OrthoFinder: To identify orthologs in different species

  • FungiDB: For fungal genomics database

  • PhylomeDB: For gene phylogeny information

• Integration approaches:

  • Cross-reference antibody-detected interaction data with bioinformatic predictions

  • Use structure predictions to map antibody epitopes

  • Integrate PTM data from antibody experiments with predicted modification sites

  • Apply machine learning to predict functions based on interaction networks

When analyzing YMR187C using these resources, consider that it is a putative protein of unknown function but has connections to cellular processes that may be relevant to neurodegeneration research .

How can YMR187C antibodies contribute to understanding protein function in the context of tauopathies?

Methodological Answer: YMR187C antibodies can provide critical insights into tauopathy mechanisms in yeast models:

• Expression correlation analysis:

  • Quantify YMR187C levels across different stages of tau pathology

  • Compare expression in conditions that enhance or suppress tau toxicity

  • Create time-course profiles during tau aggregation progression

• Stress response characterization:

  • Monitor YMR187C changes during proteotoxic stress

  • Compare responses in wild-type vs. tau-expressing yeast

  • Analyze correlation with mitochondrial dysfunction markers

• Integration with genetic screening data:

  • Use YMR187C antibody to validate hits from tau toxicity enhancer/suppressor screens

  • Analyze protein levels in mir1Δ-tau40 and other genetic backgrounds

  • Correlate with phenotypic severity in different genetic backgrounds

• Mechanistic investigations:

  • Assess YMR187C subcellular localization during tau aggregation

  • Analyze post-translational modifications in response to tau expression

  • Determine if YMR187C interacts with tau directly or indirectly

• Translational applications:

  • Test if compounds that suppress tau toxicity affect YMR187C levels or modifications

  • Assess conservation of mechanisms in mammalian neuronal models

  • Investigate if human orthologs (if identified) show similar patterns in patient samples

Research suggests that YMR187C may be linked to mitochondrial function, which is particularly relevant for tauopathies where mitochondrial dysfunction is a key pathological feature. The mir1Δ strain, which lacks the mitochondrial phosphate carrier, shows enhanced sensitivity to tau toxicity, potentially implicating YMR187C in related pathways .

How might computational approaches improve YMR187C antibody design and application?

Methodological Answer: Computational methods are revolutionizing antibody design and can be applied to YMR187C research:

• Epitope prediction and optimization:

  • Apply machine learning algorithms to identify optimal epitopes for antibody generation

  • Use structural modeling to predict accessible regions of YMR187C

  • Design antibodies targeting multiple epitopes for improved detection

• Specificity engineering:

  • Implement biophysics-informed modeling to predict antibody-antigen interactions

  • Use computational approaches to identify potential cross-reactivity

  • Apply deep learning models to optimize antibody sequences for specific binding profiles

• Experimental design optimization:

  • Use in silico modeling to predict optimal experimental conditions

  • Apply statistical methods to design minimal but comprehensive validation experiments

  • Develop algorithms for automated analysis of antibody validation data

• Integration with high-throughput data:

  • Correlate antibody binding data with proteomics and transcriptomics datasets

  • Design antibodies that can distinguish between different post-translational modifications

  • Create computational frameworks for interpreting complex antibody-based experiments

Recent advances demonstrate the feasibility of designing antibodies with customized specificity profiles, either with specific high affinity for particular target ligands or with cross-specificity for multiple targets. These approaches combine biophysics-informed modeling with extensive selection experiments, offering powerful tools for creating antibodies with desired binding properties .

What are the future prospects for using YMR187C in drug discovery for tauopathies?

Methodological Answer: YMR187C research has promising applications in drug discovery for tauopathies:

• High-throughput screening platforms:

  • Develop YMR187C-based readouts for compound screening

  • Utilize mir1Δ-tau40 yeast strains which have shown suitability for drug discovery screening

  • Incorporate into Global Platform Screening for Drug Discovery (GPSD2™) methodology

• Target validation approaches:

  • Use YMR187C antibodies to validate hits from phenotypic screens

  • Assess whether compounds affect YMR187C levels, modifications, or interactions

  • Correlate changes in YMR187C with tau toxicity suppression

• Translation to neuronal models:

  • Identify human homologs of YMR187C-associated pathways

  • Test promising compounds in mammalian neuronal models

  • Validate mechanisms using antibodies against human orthologs

• Case study example:

  • Research has identified marine bacterial extracts as suppressors of tau toxicity in mir1Δ-tau40 yeast strains

  • These extracts represent potential starting points for drug discovery and development programs

  • YMR187C antibodies could help elucidate their mechanisms of action

• Emerging approaches:

  • Combine YMR187C research with systems biology approaches

  • Develop computational models of YMR187C-associated pathways

  • Apply network pharmacology to identify multi-target therapeutic strategies